TScan Therapeutics, Inc. (TCRX) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 7 Buy, 1 Hold.
The consensus price target is $7.50 (low: $3.00, high: $12.00), representing an upside of 607.5% from the current price $1.06.
Analysts estimate Earnings Per Share (EPS) of $-1.27 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.14 vs est $-1.27 (beat +10.4%). 2025: actual $-1.00 vs est $-1.21 (beat +17.7%). Analyst accuracy: 83%.
TCRX Stock — 12-Month Price Forecast
$7.50
▲ +607.55% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for TScan Therapeutics, Inc., the average price target is $7.50, with a high forecast of $12.00, and a low forecast of $3.00.
The average price target represents a +607.55% change from the last price of $1.06.
Highest Price Target
$12.00
Average Price Target
$7.50
Lowest Price Target
$3.00
TCRX Analyst Ratings
Buy
Based on 8 analysts giving stock ratings to TScan Therapeutics, Inc. in the past 3 months
EPS Estimates — TCRX
83%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.14
vs Est –$1.27
▲ 11.6% off
2025
Actual –$1.00
vs Est –$1.21
▲ 21.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — TCRX
82%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.003B
vs Est $0.004B
▼ 28.1% off
2025
Actual $0.010B
vs Est $0.011B
▼ 8.0% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
